Patrick Borgen, MD, says this is due to earlier diagnoses, better class prediction through genomic profiling and characteristics of the disease, as well as targeted therapies.
Patrick Borgen, MD, chair, Department of Surgery, director, Maimonides Breast Cancer Center, talks about how breast cancer is becoming less of a surgical disease and more of a medical disease. Borgen says this is due to earlier diagnoses, better class prediction through genomic profiling and characteristics of the disease, as well as targeted therapies.
Borgen says the sequence for treating breast cancer has shifted as well. The sequence has historically been surgery, therapy and then radiation, though more and more patients are starting with treatment. Borgen says these treatments are capable of sterilizing the disease and, alongside medical professionals’ greater understanding of the disease, treatment has become better over the years.
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen